BRPI0417231A - método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente - Google Patents

método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente

Info

Publication number
BRPI0417231A
BRPI0417231A BRPI0417231-0A BRPI0417231A BRPI0417231A BR PI0417231 A BRPI0417231 A BR PI0417231A BR PI0417231 A BRPI0417231 A BR PI0417231A BR PI0417231 A BRPI0417231 A BR PI0417231A
Authority
BR
Brazil
Prior art keywords
chagas disease
patient
qualifying
disease status
progression
Prior art date
Application number
BRPI0417231-0A
Other languages
English (en)
Inventor
Momar Ndao
Brian Ward
Rebecca Caffrey
Terence Spithill
Hongashan Li
Vladimir Podust
Regis Perichon
Original Assignee
Ciphergen Biosystem Inc
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciphergen Biosystem Inc, Univ Mcgill filed Critical Ciphergen Biosystem Inc
Publication of BRPI0417231A publication Critical patent/BRPI0417231A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)

Abstract

"MéTODO PARA QUALIFICAR ESTADO DA DOENçA DE CHAGAS EM UM PACIENTE KIT, PRODUTO DO SOFTWARE, BIOMOLéCULA PURIFICADA, E, MéTODOS PARA QUALIFICAR ESTADO DA DOENçA DE CHAGAS E PARA MONITORAR O CURSO DE PROGRESSãO DA DOENçA DE CHAGAS EM UM PACIENTE". A presente invenção fornece biomarcadores com base em proteína e combinações de biomarcador que são úteis na qualificação do estado da doença de Chagas em um paciente. Em particular, os biomarcadores desta invenção são úteis para a classificação de uma amostra de paciente como infectada com doença de Chagas ou não infectado. Os biomarcadores podem ser detectados pela espectrometria de massa SELDI.
BRPI0417231-0A 2003-12-05 2004-12-06 método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente BRPI0417231A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52715303P 2003-12-05 2003-12-05
US56509304P 2004-04-22 2004-04-22
US62551904P 2004-11-06 2004-11-06
PCT/US2004/040990 WO2005055812A2 (en) 2003-12-05 2004-12-06 Serum biomarkers for chagas disease

Publications (1)

Publication Number Publication Date
BRPI0417231A true BRPI0417231A (pt) 2007-04-17

Family

ID=34682161

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417231-0A BRPI0417231A (pt) 2003-12-05 2004-12-06 método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente

Country Status (6)

Country Link
US (2) US8043825B2 (pt)
EP (1) EP1718763B1 (pt)
AT (1) ATE525478T1 (pt)
BR (1) BRPI0417231A (pt)
CA (1) CA2547861A1 (pt)
WO (1) WO2005055812A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178526A1 (en) * 2005-07-20 2007-08-02 Kountakis Stilianos E Use of protein profiles in disease diagnosis and treatment
WO2007070809A2 (en) * 2005-12-12 2007-06-21 Mcgill University Biomarkers for babesia
WO2009059409A1 (en) * 2007-11-05 2009-05-14 The Royal Institution For The Advancement Of Learning/Mcgill University Biomarkers for visceral leishmaniasis
JP2009244154A (ja) * 2008-03-31 2009-10-22 Nationa Hospital Organization 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法
US8426151B2 (en) * 2010-02-10 2013-04-23 Companion Diagnostics Inc. Systems and methods for the detection of biomarkers
WO2015006752A1 (en) * 2013-07-12 2015-01-15 The Regents Of The University Of California Combination therapies for malaria
CN108393195B (zh) * 2018-02-06 2020-03-20 常州大学 一种湿法脱除pm2.5装置

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705751A (en) * 1983-12-28 1987-11-10 Wisconsin Alumni Research Foundation Process for preparation of multimeric plasma fibronectin
US5281522A (en) * 1988-09-15 1994-01-25 Adeza Biomedical Corporation Reagents and kits for determination of fetal fibronectin in a vaginal sample
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
CA2163426C (en) 1993-05-28 2005-11-01 T. William Hutchens Method and apparatus for desorption and ionization of analytes
US5786156A (en) * 1993-12-21 1998-07-28 Perimmune Holdings, Inc. Immunoreactive peptides of APO(A)
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
AU714435B2 (en) * 1994-09-14 2000-01-06 Baylor College Of Medicine Methods and compositions for identifying streptococcus containing a cysteine protease or fragment thereof
WO1999041610A1 (en) * 1998-02-16 1999-08-19 Fundação Hemocentro de Ribeirão Preto Serological diagnosis of chagas' disease
US6156546A (en) * 1997-05-16 2000-12-05 Washington State University Research Foundation Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6537749B2 (en) 1998-04-03 2003-03-25 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
EP0976763B1 (en) * 1998-07-30 2003-11-05 Innogenetics N.V. Antigens and immunoassays for diagnosing Chagas' disease
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU779635B2 (en) 1999-10-27 2005-02-03 Health Discovery Corporation Methods and devices for identifying patterns in biological systems and methods for uses thereof
US20030078192A1 (en) * 2000-02-03 2003-04-24 Winter Gregory Paul Combinatorial protein domains
AU2001280581A1 (en) 2000-07-18 2002-01-30 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
WO2002042733A2 (en) * 2000-11-16 2002-05-30 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
KR20040054609A (ko) * 2001-02-16 2004-06-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 유전자 발현 프로파일을 단백질 발현 프로파일과연관시키는 방법
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US7179605B2 (en) * 2001-11-23 2007-02-20 Nanogen Inc. Fibronectin precursor biopolymer markers indicative of alzheimer's disease
US7094549B2 (en) * 2001-11-23 2006-08-22 Syn X Pharma, Inc. Fibronectin biopolymer marker indicative of insulin resistance
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
CN103969449B (zh) * 2002-08-06 2016-11-23 约翰霍普金斯大学 用于检测卵巢癌的生物标记的用途
BR0316231A (pt) * 2002-11-12 2005-10-04 Becton Dickinson Co Métodos para determinar o estado de sepsia para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo e para isolar um biomarcador, perfil biomarcador r kit
WO2004055198A2 (en) * 2002-12-12 2004-07-01 Chiron Corporation Device and method for in-line blood testing using biochips
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
WO2006022895A2 (en) * 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer

Also Published As

Publication number Publication date
EP1718763A2 (en) 2006-11-08
ATE525478T1 (de) 2011-10-15
US20120172356A1 (en) 2012-07-05
US8043825B2 (en) 2011-10-25
WO2005055812A2 (en) 2005-06-23
EP1718763A4 (en) 2009-02-25
CA2547861A1 (en) 2005-06-23
US20050260691A1 (en) 2005-11-24
WO2005055812A3 (en) 2005-09-15
EP1718763B1 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
IL229974A0 (en) Ovarian cancer biomarkers: 3ctap-related proteins
CA2602088C (en) Biomarkers for ovarian cancer and endometrial cancer
WO2014037924A3 (en) Analysis of saliva proteome for biomarkers of gingivitis and periodontitis using ft-icr-ms/ms
WO2006034032A3 (en) Biomarkers for breast cancer
WO2009151628A3 (en) Monitoring tcr-b to determine hiv therapy and disease progression
EP4249605A3 (en) Methods for analyte detection
WO2007002535A8 (en) Biomarkers for ovarian cancer
WO2007002527A3 (en) BIOMARKERS FOR OVARIAN CANCER: β-2 MICROGLOBULIN
WO2007035766A3 (en) Biomarker for prostate cancer
WO2014201516A3 (en) Biomarker identification
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2007018843A3 (en) Methods and compositions for diagnosis and treatment of influenza
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2009083950A3 (en) Biomarkers for the prediction of renal injury
WO2013052505A3 (en) Methods and devices for assessing risk to a putative offspring of developing a condition
BR112018067435A2 (pt) kit de espectrometria de massa
MX2009011494A (es) Marcadores de enfermedades.
WO2014207049A3 (de) Verfahren zur bestimmung von proteinaggregaten unter verwendung von oberflächen-fida
WO2013153461A3 (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
WO2013026026A3 (en) Shift correction for spectral analysis
ES2674177T3 (es) Preparación de suero
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders
EA201171178A1 (ru) Устройство и способ для определения и количественного анализа аналитов, в частности, микотоксинов
WO2006034264A3 (en) Methods of using sulfur nucleophiles as improved alternatives to sodium bisulfite for methylated dna analysis
WO2012164525A3 (en) Aging biomarkers

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE.